Skip to main content

Table 1 Medications in use before the enrollment for the 16-week period of run-in

From: Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial

 

Dapagliflozin

Glibenclamide

p

Metformin, %

96

98

1.0

Sulfonylureas, %

41

49

0.5

DPP-4i, %

4

14

0.16

Pioglitazone, %

2

0

1.0

ACEi, %

6

2

0.6

ARB, %

50

50

1.0

Statins, %

45

43

1.0

  1. DPP-4i dipeptidyl peptidase-4 inhibitors, ACEi angiotensin-converting-enzyme inhibitor, ARB angiotensin-receptor blockers
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us